Sage (SAGE) Reiterated at Market Perform by Raymond James, Analyst Sees Significant Risks to zuranolone Approval, Even If Approved, Size of Commercial Opportunity Questionable
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated a Market Perform rating and {REMOVEPT} price target on Sage Therapeutics (NASDAQ: SAGE)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
